Justin Bekelman, MD researches the quality, comparative effectiveness, and cost of treatment for prostate, breast, lung and other prevalent cancers. His research integrates methods from the fields of epidemiology, clinical trials, health economics, and public policy.

Dr. Bekelman leads the multi-institution Radiation Comparative Effectiveness Consortium (RADCOMP), a clinical trial network for breast cancer treatment. He also co-leads the multi-center PARTIQoL randomized trial comparing patient-reported outcomes after proton therapy for prostate cancer, versus intensity-modulated radiotherapy. 

Dr. Bekelman has received research funding from the National Cancer Institute, the Patient-Centered Outcomes Research Institute, the American Cancer Society, and philanthropic sources. He did his undergraduate work at Princeton University in the Woodrow Wilson School of Public and International Affairs and his medical training at Yale University, Johns Hopkins, and Memorial Sloan Kettering Cancer Center. Previously, he was a management consultant at the Kalchas Group, advising senior executives of health care and insurance clients on corporate strategy. Dr. Bekelman also served as Special Assistant to the Under Secretary of Defense in the US Department of Defense.

In addition to his LDI affiliation, Dr. Bekelman is Faculty in the Center for Health Incentives and Behavioral Economics, and a Senior Fellow at the Penn Center for Precision Medicine.